Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis

Abstract Background In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary interruptions of baricitinib and placebo-matched tablets in phase 3 studies...

Full description

Bibliographic Details
Main Authors: Paul Emery, Yoshiya Tanaka, Tracy Cardillo, Douglas Schlichting, Terence Rooney, Scott Beattie, Cameron Helt, Josef S. Smolen
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
DMARDs (biologics)
JAK inhibitors
Drug interruption
Online Access:http://link.springer.com/article/10.1186/s13075-020-02199-8

Internet

http://link.springer.com/article/10.1186/s13075-020-02199-8

Similar Items